- Home
- SRZN vs RPID Comparison
SRZN vs RPID Comparison
Compare SRZN & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- RPID
- Stock Information
- Founded
- SRZN 2015
- RPID 2006
- Country
- SRZN United States
- RPID United States
- Employees
- SRZN N/A
- RPID N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- RPID Medical Specialities
- Sector
- SRZN Health Care
- RPID Health Care
- Exchange
- SRZN Nasdaq
- RPID Nasdaq
- Market Cap
- SRZN 38.1M
- RPID 37.3M
- IPO Year
- SRZN N/A
- RPID 2021
- Fundamental
- Price
- SRZN $8.99
- RPID $1.09
- Analyst Decision
- SRZN
- RPID
- Analyst Count
- SRZN 0
- RPID 0
- Target Price
- SRZN N/A
- RPID N/A
- AVG Volume (30 Days)
- SRZN 33.9K
- RPID 114.2K
- Earning Date
- SRZN 11-06-2024
- RPID 11-01-2024
- Dividend Yield
- SRZN N/A
- RPID N/A
- EPS Growth
- SRZN N/A
- RPID N/A
- EPS
- SRZN N/A
- RPID N/A
- Revenue
- SRZN $10,000,000.00
- RPID $26,170,000.00
- Revenue This Year
- SRZN N/A
- RPID $24.34
- Revenue Next Year
- SRZN N/A
- RPID $19.49
- P/E Ratio
- SRZN N/A
- RPID N/A
- Revenue Growth
- SRZN N/A
- RPID 27.31
- 52 Week Low
- SRZN $6.00
- RPID $0.58
- 52 Week High
- SRZN $16.19
- RPID $1.34
- Technical
- Relative Strength Index (RSI)
- SRZN 45.92
- RPID 55.12
- Support Level
- SRZN $8.10
- RPID $1.01
- Resistance Level
- SRZN $10.76
- RPID $1.19
- Average True Range (ATR)
- SRZN 1.25
- RPID 0.11
- MACD
- SRZN -0.16
- RPID -0.02
- Stochastic Oscillator
- SRZN 22.90
- RPID 30.30
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.